Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (GB:0A4C)
LSE:0A4C
0A4C Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.30 - $11.16
Previous CloseN/A
Volume16.73K
Average Volume (3M)69.00
Market Cap
$398.16M
Enterprise Value$383.54M
Total Cash (Recent Filing)$735.12K
Total Debt (Recent Filing)$18.28M
Price to Earnings (P/E)―
Beta2.89
Next Earnings
May 08, 2025EPS Estimate
-0.36Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding77,013,660
10 Day Avg. Volume0
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)22372.47
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.18K
Enterprise Value/Ebitda-4.05
Forecast
1Y Price Target
$21.86Price Target Upside408.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial PositionAltimmune's strong financial position ensures that the IMPACT readout and subsequent FDA interactions are fully funded.
Market PositionThe scarcity of GLP/glucagon agonists puts Altimmune in a favorable position.
Product DifferentiationPemvidutide could be the first incretin-based therapy to achieve fibrosis improvement at 24 weeks, setting it apart from both GLP-1 monotherapies and other liver-directed agents.
Bears Say
Market CompetitionThe highly-anticipated Phase 2b trial (IMPACT) readout is a key near-term catalyst for investors.
Stock ValuationAnalysts view Altimmune's valuation as underappreciated given pemvidutide's potential as a potent and differentiated MASH drug.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.90% Insiders
10.56%
Mutual Funds
8.07% Other Institutional Investors
67.33% Public Companies and
Individual Investors
0A4C FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest share price was $4.30 and its highest was $11.15 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $398.16M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Feb 27, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.002.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.36.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 77,013,660 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in GB:0A4C
---
Altimmune Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.86 (408.37% Upside)
$21.86 (408.37% Upside)
Blogger Sentiment
Bullish
GB:0A4C Sentiment 87%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $57.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.97%
12-Months-Change
Fundamentals
Return on Equity
-59.86%
Trailing 12-Months
Asset Growth
-33.87%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
---
0A4C Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Altimmune's pipeline with new INDs and a strong financial position. However, challenges such as increased expenses and a net loss, along with the retirement of a key executive, were noted.Read More>---
0A4C Stock 12 Month Forecast
Average Price Target
$21.86
▲(408.37% Upside)
Technical Analysis
Autolus Therapeutics
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Inventiva
―
Sana Biotechnology
―
Best Analysts Covering 0A4C
1 Year
1 Year Success Rate
13/35 ratings generated profit
1 Year Average Return
+2.83%
reiterated a buy rating 3 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 37.14% of your transactions generating a profit, with an average return of +2.83% per trade.
---